Laura Graham, MD
Medical Oncology · Aurora, CONPI 1962896555
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,650 of the $1,830 with a category attached, or 90.2%. Astellas Pharma Global Development accounts for 90.2% of it on its own, with 2 other manufacturers making up the rest.
Across 3 payments — averaging $610.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma Global Development$2K
- AVEO Pharmaceuticals, Inc.$151
- AstraZeneca$29
Across 9 payments — averaging $21,283 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$124K
- Pfizer$45K
- Seagen Inc.$23K
What the payments were for
- Consulting fees$1,65090%
- Food & beverage$18010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma Global Development | 1 | $1,650 |
| AVEO Pharmaceuticals, Inc. | 1 | $151 |
| AstraZeneca | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,830 in reported general payments places this provider in the 55th percentile of 96 medical oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 15 | $364,713 |
| Abiraterone Acetate | 196 | $213,305 |
| EliquisApixaban | 11 | $15,364 |
| Prednisone | 95 | $794 |
| Tamsulosin Hcl | 23 | $318 |
| Potassium Chloride | 21 | $295 |
| Ondansetron Hcl | 14 | $240 |
| Prochlorperazine Maleate | 22 | $137 |
| Trazodone Hcl | 15 | $85 |
| Losartan Potassium | 11 | $48 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Aurora
- David CamidgeAurora$648K
- Paul BunnAurora$354K
- Sapna PatelAurora$186K
- Sunnie KimAurora$81K
- Virginia BorgesAurora$68K
- Erin SchenkAurora$63K
- Karl LewisAurora$62K
- Jose PachecoAurora$50K
- Leonard GlodeAurora$49K
- Robert DoebeleAurora$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.